The FORA G30a Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the following alternative sites: the palm, the forearm, the upper-arm, the calf and the thigh. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The alternative site testing in the FORA G30a Blood Glucose Monitoring System can be used only during steady-state blood glucose conditions.

Device Description

The system consists of three main products: the meter, test strips, and control solutions. These products have been designed, tested, and proven to work together as a system to produce accurate blood glucose test results. Use only FORA G30a test strips and control solutions with the FORA G30a Blood Glucose Monitoring System.

AI/ML Overview

The provided text describes a 510(k) summary for the FORA G30a Blood Glucose Monitoring System. However, it does not contain specific acceptance criteria, comprehensive performance data, or detailed study methodology in the way requested by the user's template.

The document primarily focuses on demonstrating substantial equivalence to a predicate device (FORA G30 Blood Glucose Monitoring System, K090187) due to minor modifications (software and labeling changes). It states that the FORA G30a has the "same performance characteristics" and that "A comparison of system accuracy performance demonstrated that the FORA G30a blood glucose monitoring system and the currently marketed FORA G30 Blood Glucose Monitoring System (cleared under K090187) are substantially equivalent."

Therefore, based on the provided text, it's impossible to fill in all the requested information. I can, however, extract the limited information present and point out what is missing.

Here's the breakdown based on the provided text:

Acceptance Criteria and Study Information (Based on provided text)

Information Category	Details (from provided text)	Missing Information / Not Explicitly Stated
1. Table of Acceptance Criteria & Reported Device Performance	The document states: - "FORA G30a blood glucose monitoring system has the same performance characteristics as the predicate device." - "A comparison of system accuracy performance demonstrated that the FORA G30a blood glucose monitoring system and the currently marketed FORA G30 Blood Glucose Monitoring System (cleared under K090187) are substantially equivalent."	No specific quantitative acceptance criteria for accuracy (e.g., % within +/- X mg/dL or % within +/- Y% compared to a reference method) are provided in this summary. No specific reported device performance metrics for FORA G30a (e.g., accuracy percentages, bias, precision) are explicitly stated in a table format. The claim is based on equivalence to the predicate.
2. Sample size used for the test set and data provenance	Not explicitly stated for performance testing. The provenance is likely global given "Taipei County, Taiwan" for the submitter and "China (Taiwan)" in the FDA letter.	Specific sample size for the test set is not provided. Specific data provenance (country of origin of participants, retrospective/prospective nature) for the performance study is not detailed.
3. Number of experts used to establish ground truth & qualifications	Not applicable/Not mentioned, as this is a blood glucose monitoring system for quantitative measurement, not an AI diagnostic imaging device requiring expert interpretation for ground truth.	Not applicable in the context of a blood glucose meter's performance study. Ground truth for blood glucose meters typically involves a laboratory reference method.
4. Adjudication method	Not applicable, for the same reasons as above.	Not applicable.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done	No, this is not an MRMC study. It is a blood glucose meter performance study.	Not applicable.
6. If a standalone (algorithm only) performance was done	Yes, the "system accuracy performance" mentioned would refer to the standalone performance of the blood glucose monitoring system (meter + strips). Human-in-the-loop is not a relevant concept for this type of device in the same way it is for AI-assisted image analysis.	The "standalone" nature would imply the system is tested on its own against a reference. No specific "algorithm only" performance would be separately evaluated as the algorithm is inherent to the device's function.
7. The type of ground truth used	While not explicitly stated, for blood glucose monitoring systems, the ground truth is universally established by a laboratory reference method (e.g., YSI analyzer) which is considered highly accurate.	The specific laboratory reference method used is not mentioned in the summary, though it is implied by "system accuracy performance."
8. The sample size for the training set	This device is not described as an AI/ML device that requires a "training set" in the traditional sense. It's an electrochemical biosensor with pre-programmed algorithms. The software modification mentioned implies updates to the existing algorithm, not a machine learning model requiring new training data.	Not applicable. The device is not presented as an AI/ML device requiring a training set. The "software verification and validation testing" refers to confirming the functionality and accuracy of the device's embedded software.
9. How the ground truth for the training set was established	Not applicable, as no training set (in the AI/ML sense) is mentioned.	Not applicable.

Summary of what the document does convey:

Device Name: FORA G30a Blood Glucose Monitoring System
Intended Use: Quantitative measurement of glucose in fresh capillary whole blood from the finger and alternative sites (palm, forearm, upper-arm, calf, thigh) for use by healthcare professionals and people with diabetes mellitus at home. Not for diagnosis, screening, or neonates.
Predicate Device: FORA G30 Blood Glucose Monitoring System (K090187)
Modifications: Software modification in the glucose meter and a corresponding labeling change.
Performance Claim: Substantial equivalence to the predicate device in performance, with the FORA G30a having the "same performance characteristics." Software verification and validation confirmed this.
Test Principle: Electrochemical biosensor technology using glucose oxidase.

The provided 510(k) summary is typical for a device demonstrating substantial equivalence based on minor changes to an already cleared predicate device. It relies heavily on the predicate's established performance without reiterating all specific performance criteria and detailed study results, as the expectation is that the minor changes did not alter these characteristics. To get the detailed acceptance criteria and performance data, one would typically need to review the original 510(k) submission for the predicate device (FORA G30, K090187).

Summary

{0}------------------------------------------------

Section 11. 510(k) Summary

510(K) SUMMARY

JUL -- 9 2010

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92.

KUDO732 The Assigned 510(k) number is: _______________________________________________________________________________________________________________________________________________

1. Submitter's Identification: TaiDoc Technology Corporation 3F, 5F, No.127, Wugong 2nd Rd., Wugu Township, Taipei County, 248, Taiwan
  Correspondence: Nicky Pan Regulatory Affairs Specialist Tel: +886-2-6625-8188 #1196 Fax: +886-2-6625-0288 Email: nicky@taidoc.com.tw

Date of submission: March 12, 2010

1. Device name:
  Proprietary name: FORA G30a blood glucose monitoring system

Regulatory information:

A. Regulation section: 21 CFR 862.1345 Glucose Test System
B. Classification: Class II
C. Product Code: CGA, Glucose Oxidase, Glucose NBW, System, Test, Blood Glucose, Over The Counter D. Panel: Chemistry (75)

{1}------------------------------------------------

1. Intended Use:
  The FORA G30a Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the following alternative sites: the palm, the forearm, the upper-arm, the calf and the thigh. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The alternative site testing in the FORA G30a Blood Glucose Monitoring System can be used only during steady-state blood glucose conditions.

1. Device Description:
  The system consists of three main products: the meter, test strips, and control solutions. These products have been designed, tested, and proven to work together as a system to produce accurate blood glucose test results. Use only FORA G30a test strips and control solutions with the FORA G30a Blood Glucose Monitoring System.

Substantial Equivalence Information:

A. Predicate device name: FORA G30 Blood Glucose Monitoring System

B. Predicate K number: K090187

C. Comparison with predicate:

The modified FORA G30a blood glucose monitoring system has the following similarities to the predicate device:

미 same operating principle,
same fundamental scientific technology, l
. incorporate the same basic circuit design,
incorporate the same materials,
1 same shelf life
packaged using the same materials, and
Manufactured by the same process.

{2}------------------------------------------------

The modifications encompass:

A modification in the software of the glucose meter 행
Labeling change due to the software modification l
1. Test Principle:

The detection and measurement of glucose in blood is by an electrochemical biosensor technology using glucose oxidase.

1. Performance Characteristics:
  FORA G30a blood glucose monitoring system has the same performance characteristics as the predicate device.

A comparison of system accuracy performance demonstrated that the FORA G30a blood glucose monitoring system and the currently marketed FORA G30 Blood Glucose Monitoring System (cleared under K090187) are substantially equivalent.

Software verification and validation testing confirmed that the performance, safety and effectiveness of the FORA G30a blood glucose monitoring system is equivalent to the predicate device.

1. Conclusion:
  Based on the information provided in this submission, the FORA G30a blood glucose monitoring system is substantially equivalent to the predicate FORA G30 Blood Glucose Monitoring System.

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract image of a stylized eagle.

Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-0609 Silver Spring, MD 20993-0002

TaiDoc Technology Corporation c/o Nicky Pan Regulatory Affairs Specialist 3F, 5F, No. 127, Wugong 2nd Rd Wugu Township Taipei County, China (Taiwan) 248

JUL 0 9 2010

Re: K100732

Trade name: FORA G30a Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose Test System Regulatory Class: Class II Product Code: NBW, CGA Dated: June 10, 2010 Received: June 10, 2010

Dear Nicky Pan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the approval of a proman controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts arrouning your addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

{4}------------------------------------------------

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Courtney C. Harper, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Section 8. Indications for Use

Indications for Use

< 100732 510(k) Number:

Device Name: FORA G30a Blood Glucose Monitoring System

Indications for Use:

The FORA G30a Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the following alternative sites: the palm, the forearm, the calf and the thigh. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The alternative site testing in the FORA G30a Blood Glucose Monitoring System can be used only during steady-state blood glucose conditions.

Prescription Use (21 CFR Part 801 Subpart D) And/Or Over the Counter Use X (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OVD)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 1.0073 510(k)

Page 1 of

Regulation Number and Section

§ 862.1345 Glucose test system.

(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.